KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBT (2017 - 2025)

Moderna (MRNA) has disclosed EBT for 9 consecutive years, with -$799.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 32.52% to -$799.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 billion through Dec 2025, up 23.26% year-over-year, with the annual reading at -$2.8 billion for FY2025, 23.26% up from the prior year.
  • EBT for Q4 2025 was -$799.0 million at Moderna, down from -$187.0 million in the prior quarter.
  • The five-year high for EBT was $5.4 billion in Q4 2021, with the low at -$2.0 billion in Q3 2023.
  • Average EBT over 5 years is $627.2 million, with a median of -$83.0 million recorded in 2024.
  • The sharpest move saw EBT soared 2717.95% in 2021, then tumbled 1791.43% in 2024.
  • Over 5 years, EBT stood at $5.4 billion in 2021, then crashed by 69.41% to $1.7 billion in 2022, then crashed by 95.77% to $70.0 million in 2023, then crashed by 1791.43% to -$1.2 billion in 2024, then surged by 32.52% to -$799.0 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$799.0 million, -$187.0 million, and -$818.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.